RxDoctor Payments Data

Jordan Patton, MD

Ophthalmology · Blue Ridge, GANPI 1659754398

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 42 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$622
  • Sun Pharmaceutical Industries Inc.$108
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$99
  • Glaukos Corporation$90
  • Carl Zeiss Meditec, Inc.$65
  • AbbVie$61
  • plus $348 from 11 others

What the payments were for

  • Speaking & faculty fees$322%
  • Food & beverage$1,36098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 40th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$534,674
Medicare patients
1,186
Services billed
4,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast48$56,754
LumiganBimatoprost40$25,653
Prednisolone Acetate463$20,552
RestasisCyclosporine22$15,456
MoxifloxacinMoxifloxacin Hcl439$10,810
Cyclosporine12$6,432
Latanoprost410$5,116
SimbrinzaBrinzolamide/Brimonidine Tart14$3,015
Travoprost15$2,911
Doxycycline Hyclate31$2,074
Loteprednol Etabonate12$2,037
Brimonidine Tartrate111$2,007
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat108$1,741
Timolol Maleate177$1,720
Dorzolamide-TimololDorzolamide/Timolol/Pf11$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$52$56,75448 claims
AbbVieLumigan, Restasis$61$41,10962 claims
AlconSimbrinza$622$3,01514 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$99$2,03712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Blue Ridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →